WO2003045396A1 - Estrogenrezeptor beta-selective agonisten zur antikatabolen therapie im alternden organismus - Google Patents
Estrogenrezeptor beta-selective agonisten zur antikatabolen therapie im alternden organismus Download PDFInfo
- Publication number
- WO2003045396A1 WO2003045396A1 PCT/EP2002/011649 EP0211649W WO03045396A1 WO 2003045396 A1 WO2003045396 A1 WO 2003045396A1 EP 0211649 W EP0211649 W EP 0211649W WO 03045396 A1 WO03045396 A1 WO 03045396A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- use according
- erß
- effects
- growth
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Definitions
- the present invention relates to the use of estrogen receptor (ER) ⁇ -selective agonists for the production of a medicament for triggering somatotropic and / or organotropic effects in the CNS, in the muscles, in the circulatory, skeletal and / or immune system in the aging organism of men and Mrs.
- ER estrogen receptor
- Estrogens can also induce sexual dimorphisms in later life. These functions do not only affect the female gender. You play one profound role also outside of the reproductive functions and affect all important organ systems, in particular also the heart and blood vessels, the CNS, the musculoskeletal system, the immune system, important endocrine glands such as the pancreas, the liver, the skin. Corresponding dimorphisms are expressed, for example, by differences in growth processes before and during sexual maturity [6]. In adulthood, they manifest themselves, among other things, in different body mass and composition, differences in protein, carbohydrate, fat and bone metabolism, as well as in differences in circulatory functions and in the immune system. Diseases of these systems occur in very different frequencies in both sexes. Examples of this are the significantly higher circulatory morbidity and mortality of the male and the higher risk of osteoporosis of the female sex. The female gender is also more affected by autoimmune diseases and degenerative diseases of the central nervous system.
- Sexually dimorphic functions come about partly through irreversible imprinting of morphological and functional features. Corresponding gender differences persist throughout life even in the absence of sex hormones. In part, sexual dimorphisms result from the modulation of functions by circulating or tissue-generated estrogens. There are numerous examples of this. Such functions are often affected by other sex hormones, e.g. B. androgens, modulated [6,7].
- estrogens can be formed from precursors in many organs and tissues from testosterone and adrenal androgens, such as androstenedione, and in several steps from dehydroepiandrosterone [8]. The latter mechanisms apply for both genders. In the male sex, the peripheral formation of estrogens far outweighs that of the gonads.
- the female organism Upon entering menopause, the female organism can only generate estrogens through the metabolic conversion of adrenal steroids, while in the male sex this is possible from gonadal (testosterone) and adrenal precursors.
- gonadal testosterone
- adrenal precursors gonadal (testosterone) and adrenal precursors.
- the secretion of testosterone in the male sex which is at least partially preserved even in old age, is probably one of the reasons why estrogen deficits appear less dramatically and later in men.
- estrogen deficiency states occur with the consequences known in the female gender, such as osteoporosis and disorders of well-being.
- Corresponding deficiency states can also occur as a result of therapeutic measures, for example through the suppression of adrenal secretion by DHEA and androstenedione by high-dose glucocorticoids [9].
- Estrogens formed in the target tissue are critically involved in the (fetal) sexual differentiation of the central nervous system [11]. A great functional importance of estrogens formed in different regions of the CNS in the sense of para- and autocrine functions can also be assumed in all phases of postnatal life.
- estrogen receptors After discovering that estrogens are specifically bound in the cell, there was the idea for several decades that there is only one estrogen receptor. It is now certain that there are several such receptors that bind estradiol specifically with high affinity and that, as transcription factors controlled by ligands, control the expression of genes. In addition, it was found that estrogen receptors not only act via their “own” binding sites on the DNA, but rather they can interact in a complex manner with other receptor proteins and their transcription factors.
- estrogen receptor beta (ERß) [15-19]
- ERß estrogen receptor beta
- Their distribution in the organism is different.
- Organs with an overweight of "ER ⁇ ” include the uterus, vagina, mammary gland, liver and pituitary gland.
- “ERß” is dominated, among other things, by the ovary, prostate, circulatory system and individual nuclei of the CNS. Most organs express both estrogen receptors (ER alpha / ER beta) [17].
- ERß loss also affected the expression of the progesterone receptor.
- the data collected is an indication that the ERß influences the formation of neural structures and functions in the phase of sexual differentiation in both sexes and controls the expression of ER ⁇ and the pattern of responses to estrogen treatment also in later life.
- Estrogens are used in oral contraceptives in combination with a progestogen to avoid unwanted pregnancies.
- Appropriate hormone treatment suppresses the body's own hormone secretion in addition to ovulation.
- a largely normal menstrual pattern is maintained by the hormonal active ingredients supplied.
- the metabolic functions of the suppressed ovarian hormones are also substituted by the active ingredients supplied.
- ethinyl estradiol or mestranol - a prodrug of ethinylestradiol - are the only estrogens used.
- An essential effect of ethinylestradiol in this context is its strong inhibitory effect on the secretion of FSH.
- ethinyl estradiol This is important in order to suppress the maturation of a follicle in the treatment cycle.
- This antigonadotropic activity of ethinyl estradiol is enhanced by the simultaneous administration of a progestogen and supplemented by an inhibition of LH secretion.
- One problem with the use of ethinylestradiol is its strong estrogenic effects in the liver [20-22]. These lead to changes in a broad spectrum of metabolic effects, including changes in bile secretion [20], the renin-angiotensin-aldosterone system [23], hepatic hemostasis factors and lipoproteins [21]. These changes are believed to be the basis of the side effects that can be associated with the use of hormonal contraceptives.
- estrogens are used as "estrogen (hormone) replacement therapy" (ERT or HRT).
- ERT or HRT estrogen (hormone) replacement therapy
- This therapy eliminates symptoms of deficiency, which are particularly manifested in a disorder of the state of health, circulatory functions and an increased breakdown of bone substance
- the classic estrogen effects on the uterus and mammary gland are undesirable with this therapy.
- the growth processes in the uterine mucosa triggered by estrogens require the simultaneous use of gestagens, since otherwise the risk of developing endometrial cancer increases [24]
- measures cannot be taken without the occurrence of disadvantages elsewhere, since gestagens in the breast, unlike in the uterus, do not inhibit proliferation in this organ [25, 26].
- HRT in combination with progestogen leads to an increased risk of developing breast cancer.
- oral contraceptives Like the use of oral contraceptives, oral ERT or HRT leads to deviations in a broad spectrum of liver functions and also leads to a measurable increase in the risk of deep vein thrombosis and the associated complications. The latter problem could not be remedied by using SERMs (raloxifene, tamoxifene), since these substances are not antiestrogenic in the liver, but act as estrogens. Tamoxifen and raloxifene are associated with a significantly increased risk of diseases as a result of disorders of blood coagulation [27, 28].
- the object of the present invention is to provide a therapy which addresses central aspects of hormone therapy with female
- the peculiarity of the invention is also demonstrated by the fact that it can be used with the male sex without significant disadvantages.
- the substances according to the invention stimulate testosterone secretion.
- Conventional estrogens inhibit the testicular secretion of testosterone.
- This object is achieved by the use according to the invention of estrogen receptor (ER) ⁇ -selective agonists for the production of a medicament for triggering somatotropic and / or organotropic effects in the CNS, in the muscles, in the circulatory, skeletal and immune systems in the aging organism of men and women solved.
- ER estrogen receptor
- the present invention also relates to a corresponding “method of treatment” for the indicated indications with ERß-selective agonists.
- the essence of therapy is the regeneration of mechanisms that trigger the development of organ functions outside of the genital tract during puberty and manifest themselves as a catabolic process in both sexes when the gonadal function declines.
- the aim of the therapy is to counteract the degradation of muscle and bone substance that occurs during aging and the reduction of important organ functions: anti-catabolic therapy.
- the activation of the GH (growth hormone / growth hormone) IGF-I axis plays an important role, as does the stimulation of adrenal and testicular androgen secretion.
- the proposed therapy can also have a beneficial effect on therapeutically induced disorders of the metabolism, for example the catabolic effects of therapy with glucocorticoids.
- the invention is based on the knowledge that estrogen receptor (ER) ⁇ -selective agonists surprisingly have effects on somatotropic and organotropic functions
- DHEA adrenal secretion by androgenic hormones
- DHEA-S androstenedione
- testicular hormone secretion (testosterone): Favorable metabolic effects, positive effects on well-being and libido.
- Lipoproteins The increase in HDL cholesterol reduces the accumulation of cholesterol in the vessel wall and thus prevents the progression of arteriosclerosis
- the ERß-selective compounds must therefore be dissociated in terms of their ability to trigger somatotropic and organotropic effects on the one hand and "classic" estrogen effects on the other hand.
- the ERß-selective compounds are used in a dosage in which they have practically no "classic" estrogen effects trigger.
- the substances to be used according to the invention have very little effect in the sense of "classic estrogens". Corresponding estrogenic properties can be investigated in the ovariectomized rat. With parenteral administration, 17 ⁇ -estradiol leads to an increase in uterine weights even at a dose of 0.1 ⁇ g ERß-selective substance to be used according to the invention has a comparable uterotropic effect only when the dosage is 1000 times higher (see Figure 1) These substances have little effect on the parameters of hepatic estrogenicity, for example the increase in angiotensinogen in the blood.
- ERß-selective properties can be investigated in non-sexually mature female and male rats.
- Classic estrogens (estradiol) and an ER ⁇ -selective substance have a positive effect on growth only at very low doses. Higher doses inhibit growth.
- An ERß-selective substance to be used according to the invention stimulates growth in the same dose range as estradiol, but does not have a comparable inhibitory effect at higher doses.
- An ERß-selective substance to be used according to the invention stimulates the secretion of IGF-I more than conventional estrogens.
- An ERß-selective substance to be used according to the invention stimulates testicular growth and prostate growth. This is a sure indication of the induction of testosterone secretion.
- Estradiol has no corresponding stimulating effects on testicular functions in any dose range.
- An ERß-selective substance to be used according to the invention stimulates the organ growth of the adrenal glands and thymus. In contrast, estradiol and an ER ⁇ -selective substance have an inhibitory effect on the thymus. The latter is an indication of the induction of glucocorticoid secretion by conventional estrogens.
- An ER-selective substance to be used according to the invention has a corresponding unfavorable effect in no dose range.
- An ER ⁇ -selective substance to be used according to the invention exerts all therapy-relevant effects in a dose range which is 10-1000 times less than that in which direct effects on the uterus or inhibitory effects the growing testicles.
- Estradiol starts ER ⁇ and ERß and creates a whole panorama of different effects; the therapy proposed here is selective; has practically no negative side effects.
- the adrenal androgen secretion can be reactivated.
- the treatment according to the invention increases the IGF-I levels in the blood and in the liver of people of old or very old age: increasing the IGF-I level has a favorable influence on all organs.
- the present invention teaches that these body and organ functions, which have developed positively in adolescence and which decline in the course of the aging process and then lead to signs of failure and clinical pictures, can be restored at least to a certain extent in people of old and very old age. Examples in this context are the loss of muscle and bone mass and the associated decrease in IGF-I, gonadal and adrenal androgen secretion (secretion of DHEA, DHEA-S, androstenedione). This is a very important point of view against the background of other medical advances that help people to live longer and longer.
- the invention makes an important contribution for the quality of life of aging people, because the invention eliminates or at least reduces organic and physical malfunctions that affect the quality of life. The proportion of people in need of care in older age groups can thus be reduced.
- the use of the ER ⁇ -selective agonists according to the invention permits the treatment of catabolic conditions in the wake of a decreased secretion of sex hormones in both men and women in old age. Furthermore, it enables the treatment of such catabolic conditions, which are caused by a deficiency in growth hormone and / or IGF.
- the treatment according to the invention with an ERß-selective agonist stimulates the secretion of growth hormone and gonadotropic hormones. Liver IGF-I secretion and blood levels of this somatotropic factor are increased.
- ERß-selective agonists When using ERß-selective agonists according to the invention, no direct estrogenic effects on sexual organs - uterus, vagina, mammary gland - are exerted at those dosages which are sufficient for the treatment of catabolic conditions. Therefore, the proposed use of an ERß agonist does not usually have to be combined with a progestogen. Indirect estrogen effects, for example through induction of LH and FSH secretion in women, appear possible, but not in postmenopause, since reactive follicles in the ovary are no longer present in this phase. Furthermore, significantly reduced effects on estrogen-regulated functions of the liver are observed.
- Agonists are not conventional estrogen replacement therapy.
- deficiency of the estrogens is not only eliminated, but the functionality of the organs in question is restored in a manner which is found in younger people, with the reproductive functions no longer relevant in older age (effects on the uterus, breast nozzle). unlike conventional estrogens.
- the basal endocrine gonadal function as well as the thymus function and the immune system are positively influenced.
- An ERß selective agonist for use in the present invention is characterized by higher affinity for the estrogen receptor of rat prostate compared to rat uterus, or by higher affinity for ERß compared to ER ⁇ .
- the present application also encompasses other estrogens which are selective for the ERß and which have been described in various patent applications or publications, for example:
- the ERß agonist is preferably selected from 3, 16-dihydroxyestra-1, 3, 5 (10) -triene derivatives (e.g. 3.16 ⁇ -dihydroxyestra-1, 3, 5 (10) -triene), 8 ⁇
- ERß antagonists are in DE 199 06 159.9 (WO 00/47603), DE 199 17 930.1 (WO 00/63228), DE 199 41 105.1 and
- the selective estrogen effect is achieved due to the different tissue distribution of ER ⁇ and ERß by the subtype-specific ligand. Substances with preference for ERß compared to ER ⁇ in the in vitro receptor binding test were described by Kuiper et al. described [29].
- the pharmaceutical preparations for the use of an ERß-selective agonist according to the invention optionally contain this in a mixture with pharmacologically customary carriers, auxiliaries or diluents, and optionally with other pharmacologically or pharmaceutically active substances.
- the pharmaceuticals are manufactured in a known manner.
- auxiliaries such as auxiliary substances for pharmacy, cosmetics and related areas:
- the compounds can be administered orally, buccally or parenterally, for example intraperitoneally, intramuscularly, subcutaneously or percutaneously.
- the connections can also be implanted into the tissue.
- the active ingredients can be dissolved or suspended in a physiologically acceptable diluent.
- a physiologically acceptable diluent Oils with or without the addition of a solubilizer, a surface-active agent, a suspending or emulsifying agent are very often used as diluents. Examples of oils used are olive oil, peanut oil, cottonseed oil, soybean oil, castor oil and sesame oil.
- the compounds can also be used in the form of a depot injection or an implant preparation, which can be formulated in such a way that a delayed release of the active substance is made possible.
- Implants can be used as inert materials such.
- B. contain biodegradable polymers or synthetic silicones such.
- the active ingredients can also be used percutaneously for. B. be incorporated into a plaster.
- Various polymers are suitable for the local administration of intravaginal (e.g. vaginal rings) or intrauterine systems (e.g. pessaries, spirals, IUS, Mirena®) loaded with active substances, such as e.g. B. silicone polymers, ethylene vinyl acetate, polyethylene or polypropylene.
- the compounds can also be formulated as cyclodextrin clathrates.
- the compounds are reacted with ⁇ , ⁇ - or y-cyclodextrin or derivatives thereof (PCT / EP95 / 02656).
- the active ingredients can also be encapsulated with liposomes.
- the binding affinity of the selective estrogens was tested in competition experiments using 3 H - estradiol as ligand on estrogen receptor preparations of rat prostate and rat uterus.
- the preparation of the prostatacytosol and the estrogen receptor test with the prostatacytosol was carried out as described by Jung-Testas et al. (1981), carried out [30].
- the ERß ligands claimed for the application in the present patent right have a higher binding affinity for the estrogen receptor ERß from rat prostate than from rat uterus (Er ⁇ ). It is assumed that ERß predominates over ER ⁇ in the rat prostate, in rat uterus ER ⁇ over ERß. In agreement with this, we find that the ratio of binding to the prostate and uterine receptor corresponds qualitatively to the ratio of the relative binding affinity (RBA) to human ERß and ER ⁇ from rat (according to Kuiper et al.) [29].
- RBA relative binding affinity
- the dosage of the ERß-selective agonist in the context of the present invention is between 10 ⁇ g and 10mg absolute daily.
- FIGS. 1 to 8 The invention is to be explained in more detail by FIGS. 1 to 8:
- the ER ⁇ -selective agonist used is consistently 3,17 ⁇ -dihydroxy-19-nor-17 ⁇ -pregna-1,3,5 (10) -triene-21, 16 ⁇ -lactone (DE 100 48 634.7).
- E 2 and ER ⁇ agon induce uterine growth at a much lower dose than the ERß agon; 0.1 ⁇ g E 2 and a factor 1000 higher dose (100 ⁇ g) of ERß-Agon have comparable "classic" estrogenic activity.
- the ERß agon has significant effects on the weight development of the uterus and vagina in extremely low doses.
- the effects of ERß-agon are statistically significantly better than those of ER ⁇ -agon and E 2 . This effect is an indication of the induction of ovarian estrogen secretion.
- FIG 3 Effects of ERß-agon or ERß-selective agonists (agon) (E 2 ) on gonads of male and female non-sexually mature rats compared to estradiol.
- Treatment of offspring after weaning for 7 days (day 1 - day 7, autopsy day 8, subcutaneous injection).
- Result The testes show a very rapid growth in the control phase in control animals, but ovaries hardly.
- E 2 inhibits the growth of the testes in a dose-dependent manner.
- the simultaneous inhibition of prostate growth reflects the suppression of testosterone secretion by E 2 .
- ERß-Agon statistically significantly stimulates testicular growth beyond normal levels.
- ERß-Agon leads to an increase in adrenal and thymus weights simultaneously over a wide dose range.
- ER ⁇ -agon and E 2 lead to less pronounced positive effects and, via "classic" estrogenicity, to a reduction in the thymus weights at higher doses.
- Figure 7 Effects of ER ⁇ - or ERß-selective agonists (agon) on the body growth of ovary-intact non-sexually mature rats in comparison to estradiol (E 2 ). Treatment of the offspring after weaning over 7 days (day 1 - day 7, autopsy day 8, subcutaneous injection) in two trials with different dose ranges.
- ERß-Agon leads to an accelerated growth of the animals over a wide dose range. Effects are more pronounced at low doses than at higher ones. In contrast, ER ⁇ agon and E 2 lead to a significant reduction in weight gain at higher doses.
- the ERß agonist used here as an example is orally bioavailable.
- Human fetal testis second trimester proliferative and steroidogenic capacities.
- mice deficient in liver production of insulin-like growth factor I display sexual dimorphism in growth hormone-stimulated postnatal growth. Endocrinology (United States), Dec 2000, 141 (12) p4436-41 [7] Span JP, Pieters GF, Sweep CG, et al.
- DHEA Dehydroepiandrosterone
- DHEA sulfate DHEA sulfate
- aging contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sei U S A (United States), Apr 11 2000, 97 (8) p4279-84
- Estrogen receptor (ER) beta a modulator of ERalpha in the uterus. Proc NatI Acad Sei U S A (United States), May 23 2000, 97 (11) p5936-41
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02772385A EP1448206A1 (de) | 2001-10-17 | 2002-10-17 | Estrogenrezeptor beta-selektive agonisten zur antikatabolen therapie im alternden organismus |
AU2002337164A AU2002337164A1 (en) | 2001-10-17 | 2002-10-17 | Estrogen receptor beta-selective agonists for anti-catabolic therapy in an aging organism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10151363.1 | 2001-10-17 | ||
DE10151363A DE10151363A1 (de) | 2001-10-17 | 2001-10-17 | Somatotrope Therapie |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003045396A1 true WO2003045396A1 (de) | 2003-06-05 |
Family
ID=7702869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/011649 WO2003045396A1 (de) | 2001-10-17 | 2002-10-17 | Estrogenrezeptor beta-selective agonisten zur antikatabolen therapie im alternden organismus |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1448206A1 (de) |
AR (1) | AR036846A1 (de) |
AU (1) | AU2002337164A1 (de) |
DE (1) | DE10151363A1 (de) |
WO (1) | WO2003045396A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011014516A1 (en) | 2009-07-28 | 2011-02-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Estrogen antagonists as treatments for sclerosing disorders |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11292872A (ja) * | 1998-04-02 | 1999-10-26 | Sumitomo Chem Co Ltd | エストロゲンレセプターβアイソフォーム活性化剤 |
WO1999063973A2 (en) * | 1998-06-11 | 1999-12-16 | Endorecherche, Inc. | PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL |
DE19906159A1 (de) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
DE19917930A1 (de) * | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
WO2000064438A1 (en) * | 1999-04-28 | 2000-11-02 | Novogen Research Pty Ltd | Cardiovascular and bone treatment using isoflavones |
DE19954105A1 (de) * | 1999-11-02 | 2001-05-17 | Schering Ag | 18-Nor-Steroide als selektiv wirksame Estrogene |
WO2001077139A1 (de) * | 2000-04-12 | 2001-10-18 | Schering Aktiengesellschaft | 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene |
WO2002046164A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic compounds |
-
2001
- 2001-10-17 DE DE10151363A patent/DE10151363A1/de not_active Withdrawn
-
2002
- 2002-10-17 WO PCT/EP2002/011649 patent/WO2003045396A1/de not_active Application Discontinuation
- 2002-10-17 EP EP02772385A patent/EP1448206A1/de not_active Withdrawn
- 2002-10-17 AR ARP020103910A patent/AR036846A1/es unknown
- 2002-10-17 AU AU2002337164A patent/AU2002337164A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11292872A (ja) * | 1998-04-02 | 1999-10-26 | Sumitomo Chem Co Ltd | エストロゲンレセプターβアイソフォーム活性化剤 |
WO1999063973A2 (en) * | 1998-06-11 | 1999-12-16 | Endorecherche, Inc. | PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL |
DE19906159A1 (de) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
DE19917930A1 (de) * | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
WO2000064438A1 (en) * | 1999-04-28 | 2000-11-02 | Novogen Research Pty Ltd | Cardiovascular and bone treatment using isoflavones |
DE19954105A1 (de) * | 1999-11-02 | 2001-05-17 | Schering Ag | 18-Nor-Steroide als selektiv wirksame Estrogene |
WO2001077139A1 (de) * | 2000-04-12 | 2001-10-18 | Schering Aktiengesellschaft | 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene |
WO2002046164A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic compounds |
Non-Patent Citations (7)
Title |
---|
CAO L ET AL: "Estrogen receptor-beta is the key receptor supporting protection of bone mass by estrogen.", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 16, no. Suppl. 1, September 2001 (2001-09-01), Twenty-Third Annual Meeting of the American Society for Bone and Mineral Research;Phoenix, Arizona, USA; October 12-16, 2001, pages S160, XP009003185, ISSN: 0884-0431 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 2001 (2001-05-01), JUUL ANDERS: "The effects of oestrogens on linear bone growth.", XP002225794, Database accession no. PREV200100315453 * |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; MORABITO N. ET AL: "Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: A randomized double-blind placebo-controlled study.", XP002225795, retrieved from STN Database accession no. 2002348410 * |
DATABASE WPI Section Ch Week 200002, Derwent World Patents Index; Class B02, AN 2000-018703, XP002225796 * |
HUMAN REPRODUCTION UPDATE, vol. 7, no. 3, May 2001 (2001-05-01), pages 303 - 313, ISSN: 1355-4786 * |
JOURNAL OF BONE AND MINERAL RESEARCH, (1 OCT 2002) 17/10 (1904-1912). * |
KUIPER GEORGE G J M ET AL: "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor alpha and beta.", ENDOCRINOLOGY, vol. 138, no. 3, 1997, pages 863 - 870, XP002225793, ISSN: 0013-7227 * |
Also Published As
Publication number | Publication date |
---|---|
AR036846A1 (es) | 2004-10-06 |
AU2002337164A1 (en) | 2003-06-10 |
DE10151363A1 (de) | 2003-05-08 |
EP1448206A1 (de) | 2004-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60216630T2 (de) | Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie | |
DE69532894T2 (de) | Verfahren zur empfängnisverhütung | |
EP0723439B1 (de) | Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen | |
DE19739916C2 (de) | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen | |
EP2552404B1 (de) | Parenterale arzneiform, die aromatasehemmer und gestagene freisetzt, für die behandlung von endometriose | |
DE60318092T2 (de) | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung | |
DE4429398C2 (de) | Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption | |
EP0799042A1 (de) | Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption | |
DE3733478A1 (de) | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore | |
EP1100509B1 (de) | Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie | |
DE60223795T2 (de) | Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption | |
WO2009138186A2 (de) | SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN | |
DE60318447T2 (de) | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung | |
WO1997032588A2 (de) | Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann | |
EP0310542B1 (de) | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren | |
DE602004009288T2 (de) | Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose | |
DE60121980T2 (de) | Verwendung von 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-on zur herstellung eines medikaments zur behandlung von brust-, eierstock-, endometrium-krebs, myelom und meningiom | |
DE4339934A1 (de) | Ovulationshemmendes Mittel zur hormonalen Kontrazeption | |
WO2003045396A1 (de) | Estrogenrezeptor beta-selective agonisten zur antikatabolen therapie im alternden organismus | |
WO2002074315A1 (de) | Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie | |
EP0889727B1 (de) | Sequentielle estrogen/progesteronantagonist-kombination für die hormonersatz-therapie | |
WO1995005828A1 (de) | PROGESTERONANTAGONISTISCH- UND ANTIÖSTROGEN WIRKSAME VERBINDUNGEN FÜR DIE BEHANDLUNG DES $i(LEIOMYOMATA UTERI) | |
DE102019115343A1 (de) | Vaginalring für die hormonelle Kontrazeption | |
Kuhl | The new progestagens–advantages and disadvantages | |
DE19510862A1 (de) | Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002772385 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002772385 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002772385 Country of ref document: EP |